Format

Send to

Choose Destination
Am J Ophthalmol. 2010 Jan;149(1):66-9. doi: 10.1016/j.ajo.2009.08.004. Epub 2009 Oct 28.

Treatment with voriconazole in 3 eyes with resistant Acanthamoeba keratitis.

Author information

1
Cataract, Cornea and External Disease Service, Wilmer Eye Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Abstract

PURPOSE:

To report the use of topical voriconazole 1% (Vfend; Pfizer Inc, New York, New York, USA) ophthalmic solution for Acanthamoeba keratitis (AK) resistant to treatment with chlorhexidine (PerioChip; Dexel Pharma Technologies, Jerusalem, Israel).

DESIGN:

Retrospective case series.

METHODS:

Three eyes of 2 patients with culture-proven AK were treated at a tertiary care institution, and their charts were reviewed. Topical voriconazole 1% was instituted as second-line treatment for AK unresponsive to standard treatment with chlorhexidine and hexamidine. Treatment with voriconazole 1% was started at 1-hour intervals. Improvement was assessed and defined by absence of clinical signs of active infection and visual improvement.

RESULTS:

One patient with unilateral AK and 1 patient with bilateral AK who remained culture-positive for Acanthamoeba despite ongoing treatment with chlorhexidine and hexamidine were treated with voriconazole 1% topical solution as an adjuvant. Both patients were contact lens wearers. Of 3 eyes additionally treated with voriconazole, 2 eyes had clinical resolution of disease. One eye demonstrated recurrent disease after penetrating keratoplasty that resolved after intrastromal injection of voriconazole.

CONCLUSIONS:

We report the use of topical and intrastromal voriconazole in successfully treating AK in cases of chlorhexidine- and hexamidine-resistant Acanthamoeba. Voriconazole may be a promising adjuvant agent in treating AK.

PMID:
19875089
DOI:
10.1016/j.ajo.2009.08.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center